Two distinct effector memory cell populations of WT1 (Wilms’ tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients
暂无分享,去创建一个
Kenji Mizuguchi | Sumiyuki Nishida | Atsushi Kumanogoh | Yusuke Oji | K. Mizuguchi | T. Kyo | N. Hosen | Y. Oji | A. Tsuboi | Y. Oka | H. Sugiyama | A. Kumanogoh | J. Nakata | S. Nishida | F. Fujiki | H. Nakajima | Naoki Hosen | Akihiro Tsuboi | Yoshihiro Oka | Haruo Sugiyama | S. Morimoto | Yoshiki Nakae | Fumihiro Fujiki | Soyoko Morimoto | Toshio Kamiya | Satoshi Takashima | Jun Nakata | Hiroko Nakajima | Taiichi Kyo | T. Kamiya | Y. Nakae | S. Takashima
[1] J. Hatazawa,et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. , 2008, Journal of neurosurgery.
[2] Marius Wernig,et al. Comprehensive qPCR profiling of gene expression in single neuronal cells , 2011, Nature Protocols.
[3] N. Weng,et al. The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation , 2012, Nature Reviews Immunology.
[4] Y. Oka,et al. WT1 peptide immunotherapy for cancer in children and young adults , 2010, Pediatric blood & cancer.
[5] J. Hatazawa,et al. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. , 2006, Japanese journal of clinical oncology.
[6] J. Sakamoto,et al. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient , 2010, European journal of haematology.
[7] K. Aozasa,et al. WT1 (WILMS TUMOR 1) PEPTIDE IMMUNOTHERAPY FOR CHILDHOOD RHABDOMYOSARCOMA: A Case Report , 2009, Pediatric hematology and oncology.
[8] I. Kawase,et al. WT1 Peptide‐Based Immunotherapy for Patients with Lung Cancer: Report of Two Cases , 2004, Microbiology and immunology.
[9] H. Goossens,et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination , 2010, Proceedings of the National Academy of Sciences.
[10] M. Takiguchi,et al. Differentiation of Human CD8+ T Cells from a Memory to Memory/Effector Phenotype1 , 2002, The Journal of Immunology.
[11] Veronica Sanchez-Freire,et al. Microfluidic single-cell real-time PCR for comparative analysis of gene expression patterns , 2012, Nature Protocols.
[12] J. Wolchok,et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. , 2010, Blood.
[13] T. Kyo,et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[14] Quin F. Wills,et al. Methods for qPCR gene expression profiling applied to 1440 lymphoblastoid single cells , 2013, Methods.
[15] D. Housman,et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor , 1990, Cell.
[16] H. Sugiyama,et al. Wilm's tumor gene WT1 peptide immunotherapy for pulmonary metastasis from adenoid cystic carcinoma of the salivary gland. , 2011, Oral oncology.
[17] S M Hewitt,et al. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. , 1995, Cancer research.
[18] D. Busch,et al. The smallest unit: effector and memory CD8+ T cell differentiation on the single cell level , 2013, Front. Immun..
[19] T. Yoshimine,et al. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. , 2010, Japanese journal of clinical oncology.
[20] I. Kawase,et al. WT1 peptide vaccine for the treatment of cancer. , 2008, Current opinion in immunology.
[21] Anders Ståhlberg,et al. Single-cell gene expression profiling using reverse transcription quantitative real-time PCR. , 2010, Methods.
[22] J. Sakamoto,et al. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial , 2013, Journal of Cancer Research and Clinical Oncology.
[23] Lokesh P. Tripathi,et al. TargetMine, an Integrated Data Warehouse for Candidate Gene Prioritisation and Target Discovery , 2011, PloS one.
[24] Y. Oji,et al. Vaccination with WT-1 (Wilms' tumor gene-1) peptide and BCG-CWS in melanoma. , 2012, European journal of dermatology : EJD.
[25] I. Kawase,et al. Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis , 2003, International journal of hematology.
[26] Thomas P. Loughran,et al. HTLV-2 Tax Immortalizes Human CD4+ Memory T Lymphocytes by Oncogenic Activation and Dysregulation of Autophagy* , 2012, The Journal of Biological Chemistry.
[27] J. Pelletier,et al. The Wilms’ Tumor Suppressor Gene (wt1) Product Regulates Dax-1 Gene Expression during Gonadal Differentiation , 1999, Molecular and Cellular Biology.
[28] H. Inohara,et al. WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer. , 2012, Anticancer research.
[29] P. Moss,et al. Memory T Cells Constitute a Subset of the Human CD8+CD45RA+ Pool with Distinct Phenotypic and Migratory Characteristics1 , 2001, The Journal of Immunology.
[30] A. Poustka,et al. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping , 1990, Nature.
[31] H. Harigae,et al. Autophagy plays a protective role as an anti‐oxidant system in human T cells and represents a novel strategy for induction of T‐cell apoptosis , 2014, European journal of immunology.
[32] J. Sakamoto,et al. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. , 2007, International journal of hematology.
[33] H. Sugiyama. Wilms’ Tumor GeneWT1: Its Oncogenic Function and Clinical Application , 2001, International journal of hematology.
[34] T. Yoshimine,et al. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients , 2010, Brain Tumor Pathology.
[35] Martin A. Cheever,et al. The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.
[36] N. Hosen,et al. WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission , 2012, Leukemia.
[37] I. Kawase,et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells , 2006, Modern Pathology.
[38] G. Soma,et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. , 2011, Anticancer research.
[39] H. Sugiyama. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. , 2010, Japanese journal of clinical oncology.
[40] T. Kyo,et al. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease , 2012, Leukemia.
[41] Y. Aizawa,et al. WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE , 2010, International journal of medical sciences.
[42] T. Yoshimine,et al. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors]. , 2009, Brain and nerve = Shinkei kenkyu no shinpo.
[43] Y. Takeda,et al. Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer , 2014, Journal of immunotherapy.
[44] S. Kyo,et al. Immunohistochemical detection of WT1 protein in endometrial cancer. , 2009, Anticancer research.
[45] A. Sharov,et al. Totipotent Embryonic Stem Cells Arise in Ground-State Culture Conditions , 2013, Cell reports.
[46] J. Sakamoto,et al. Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma , 2007 .
[47] C. Hess,et al. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch , 2013, Nature Immunology.
[48] D. Green,et al. Metabolic checkpoints in activated T cells , 2012, Nature Immunology.
[49] Z. Berneman,et al. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. , 2012, The oncologist.
[50] G I Bell,et al. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. , 1992, Science.
[51] J. Sakamoto,et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. , 2009, Anticancer research.